Heart failure in African Americans: Unique etiology and pharmacologic treatment responses

Journal of the National Medical Association

Volumn 95, Issue 1, 2003, Pages 1-12

  Yancy, Clyde W ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDRALAZINE; ISOSORBIDE DINITRATE; METOPROLOL; PLACEBO; PRAZOSIN;

ACCREDITATION; ADULT; AGED; CONTINUING EDUCATION; DOSE RESPONSE; ETHNIC GROUP; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; REVIEW; RISK BENEFIT ANALYSIS; SOCIOECONOMICS; AFRICAN AMERICAN; CONGESTIVE HEART FAILURE; ETHNOLOGY;

ADRENERGIC BETA-ANTAGONISTS; AFRICAN AMERICANS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; SOCIOECONOMIC FACTORS;

EID: 0037264219     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. American Heart Association. African-Americans and congestive diseases. Dallas, TX: American Heart Association; 1999.
2. Congestive heart failure in the United States: A new epidemic. Bethesda, MD: National Heart, Lung and Blood Institute; 1996.
3. Yancy CW. Heart failure in African Americans: a cardiovascular engima. J Card Fail. 2000;6:183-186.
4. Dries DL, Exner DV, Gersh BJ, et al. Racial differences in the outcome of left ventricular dysfunction [published erratum appears in N Engl J Med. 1999 Jul 22;341(4):298]. N Engl J Med. 1999;340:609-616.
5. Exner DV, Dries DL, Domanski MJ, et al. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med. 2001;344:1351-1357.
6. Bourassa MG, Gurne O, Bangdiwala SI, et al. Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. J Am Coll Cardiol. 1993;22:14A-19A.
7. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345-352.
8. Carson P, Ziesche S, Johnson G, et al. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail. 1999;5:178-187.
9. Saunders E. Hypertension in minorities: blacks. Am J Hypertens. 1995;8:115s-119s.
10. He FJ, Markandu ND, Sagnella GA, et al. Importance of the renin system in determining blood pressure fall with salt restriction in black and white hypertensives. Hypertension 1998;32:820-824.
11. Pratt JH, Manatunga AK, Bowsher RR, et al. The interaction of norepinephrine excretion with blood pressure and race in children. J Hypertens. 1992;10:93-96.
12. Voors AW, Berenson GS, Dalferes ER, et al. Racial differences in blood pressure control. Science. 1979;204:1091-1094.
13. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
14. Mason DA, Moore JD, Green SA, et al. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem. 1999;274:12670-12674.
15. Moore JD, Mason DA, Green SA, et al. Racial differences in the frequencies of cardiac beta(1)-adrenergic receptor polymorphisms: analysis of c145A>G and c1165G>C. Hum Mutat. 1999;14:271.
16. Lang CC, Stein CM, He HB, et al. Blunted blood pressure response to central sympathoinhibition in normotensive blacks: increased importance of nonsympathetic factors in blood pressure maintenance in blacks. Hypertension. 1997;30:157-162.
17. Stein CM, Lang CC, Nelson R, et al. Vasodilation in black Americans: attenuated nitric oxide-mediated responses. Clin Pharmacol Ther. 1997;62:436-443.
18. Suthanthiran M, Li B, Song JO, et al. Transforming growth factor-beta1 hyperexpression in African-American hypertensives: a novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci (USA). 2000;97:3479-3484.
19. Gainer JV, Morrow JD, Loveland A, et al. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 1998;339:1285-1292.
20. Sica DA, Douglas JG. The African American Study of Kidney Disease and Hypertension (AASK): new findings. J Clin Hypertens (Greenwich). 2001;3:244-251.
21. Basile JN. Blacks with hypertension, renal insufficiency, and baseline proteinuria benefit more from ACE inhibition than from calcium channel blockade. J Clin Hypertens (Greenwich). 2001;3:315-316.
22. Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - pharmacological approaches. J Card Fail. 1999;5:357-382.
23. ACTION HF. Optimal management of heart failure: A CME study guide. 1998.
24. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-1667.
25. Yancy CW, Fowler MB, Colucci WS, et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med. 2001;344:1358-1365.
26. Packer M, Antonopoulos GV, Berlin JA, et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: Results of a meta-analysis. Am Heart J. 2001;141:899-907.
27. Wedel H, Demets D, Deedwania P, et al. Challenges of subgroup analyses in multinational clinical trials: Experiences from the MERIT-HF trial. Am Heart J. 2001;142:502-511.
28. Ruffolo RR Jr, Gellai M, Hieble JP, et al. The pharmacology of carvedilol. Eur J Clin Pharmacol. 1990;38 (sSuppl 2):S82-S88.
29. Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 1992;263:92-98.